KR20060102175A - Cosmetic composition for whitening of the skin having silanoyl oxymethyl-methyl imidazole derivatives - Google Patents

Abstract

The present invention relates to a cosmetic composition for skin whitening, and more particularly, to a composition for inhibiting melanin production and a cosmetic composition for skin whitening comprising a silanoyl oxymethyl-methyl imidazole derivative represented by the following Formula 1 as an active ingredient: will be.

The cosmetic composition for skin whitening of the present invention suppresses melanin production of the skin, and is very excellent in improving blemishes and freckles and skin whitening effect.

[Formula 1]

(Wherein R ₁ , R ₂ and R ₃ are as defined in the specification).

Melanin, skin whitening, cosmetics

Description

Cosmetic composition for whitening of skin comprising silanoyl oxymethyl-methyl imidazole derivatives

[Industrial use]

The present invention relates to a composition for inhibiting melanin production and a cosmetic composition for skin whitening, which are excellent in improving skin and freckles and skin whitening effect by inhibiting melanin production of the skin.

[Private Technology]

It is everyone's constant desire to have white, fair skin. Human skin color is genetically determined by the concentration and distribution of melanin in the skin, but is also influenced by environmental or physiological conditions such as solar ultraviolet rays, fatigue and stress. Melanin is produced through a non-enzymatic oxidation reaction after tyrosine, an amino acid, acts as an enzyme called tyrosinase, transforming it into dopa and dopaquinone. However, although the pathway by which melanin is made is known, it is still not clear what mechanism is responsible for inducing melanin synthesis, the previous step in which tyrosinase works.

    Therefore, conventionally, a substance having a tyrosinase inhibitory activity such as hydroquinone, ascorbic acid, kojic acid, glutathione, and the like is added to the ointment or cosmetics to make skin whitening, blemishes, and freckles. Although it has been used for the purpose of improvement, the use is limited because it causes skin irritation or poor product stability, and also has a weak effect.

    Therefore, the present inventors have tried to develop a new whitening agent using a mouse melanoma cell (B16 mouse melanoma cell) that can screen even a substance that inhibits melanin synthesis induction itself, silanyl oxymethyl -Methyl imidazole derivatives have been found to have a very strong melanin production inhibitory effect and whitening effect to complete the present invention.

The present invention is to solve the conventional problems as described above, an object of the present invention is to provide a composition for inhibiting melanin production to inhibit melanin production of the skin.

It is another object of the present invention to provide a cosmetic composition for skin whitening, which is excellent in reducing the melanin and improving freckles and freckles and skin whitening effect.

In order to achieve the above object, the present invention provides a composition for inhibiting melanin production comprising silanoyl oxymethyl-methyl imidazole derivative represented by the following formula (1) as an active ingredient.

The present invention also provides a cosmetic composition for skin whitening comprising silanoyl oxymethyl-methyl imidazole derivative represented by the following formula (1) as an active ingredient.

(Wherein R _1, R ₂ and R ₃ may be the same or different from each other, hydrogen atom, C ₃ to C ₇ straight or branched chain alkyl group, C ₂ to C ₇ linear or branched form of alkenyl groups and C ₅ to C of Selected from the group consisting of ₇ cycloalkenyl groups,

n is an integer of 0 or 1.)

Preferably, R ₁ , R ₂ and R ₃ are selected from the group consisting of a hydrogen atom, an alkyl group of C ₁ to C ₄ , an alkenyl group of C ₂ to C ₅ and a phenyl group,

n is an integer of 0 or 1.

More preferably, the silanoyl oxymethyl-methyl imidazole derivatives according to the invention are as follows:

1) tertiarybutyldiphenylsilaneyloxymethyl-5-methyl-1-imidazole

2) diphenylsilaneyl oxymethyl-5-methyl-1-imidazole

3) dimethyldimethylsilaneyl oxymethyl-5-methyl-1-imidazole

4) methyltriphenylsilaneyloxymethyl--5-methyl-1-imidazole

5) diphenylvinylsilaneyloxymethyl--5-methyl-1-imidazole

6) methyl-methylphenylsilanyloxymethyl--5-methyl-1-imidazole

7) methyl-methyldiphenylsilaneyloxymethyl--5-methyl-1-imidazole

8) Dimethylparatoylsilaneyloxymethyl--5-methyl-1-imidazole

Such compounds are as shown in Table 1 below.

Compound name constitutional formula Tertiarybutyldiphenylsilaneyloxymethyl-5-methyl-1-imidazole

Diphenylsilaneyl oxymethyl-5-methyl-1-imidazole

Dimethylphenylsilanyl oxymethyl-5-methyl-1-imidazole

Methyltriphenylsilaneyloxymethyl--5-methyl-1-imidazole

Diphenylvinylsilaneyloxymethyl--5-methyl-1-imidazole

Methyl-methylphenylsilanyloxymethyl--5-methyl-1-imidazole

Methyl-methyldiphenylsilaneyloxymethyl--5-methyl-1-imidazole

Dimethylparatoylsilaneyloxymethyl--5-methyl-1-imidazole

The silanoyl oxymethyl-methyl imidazole derivatives represented by the formula (1) are known materials already described in various literatures, but there are no reports on melanin inhibitory effects.

Thus, the silanoyl oxymethyl-methyl imidazole derivatives of the formula (1) may be purchased and used commercially, or may be prepared and used by known methods, and may be purified. The purification used at this time can be carried out by methods such as commonly used column chromatography and high performance liquid chromatography (HPLC), but is not limited to these methods.

For example, the silanoyl oxymethyl-methyl imidazole derivative represented by Chemical Formula 1 is prepared by the reaction as described in Scheme 1 below.

(Wherein R ₁ , R ₂ and R ₃ are as defined above and X is a halogen element.)

Preferably, the imidazole derivative represented by Chemical Formula 2 and the silane compound represented by Chemical Formula 3 are dissolved in a solvent under a catalyst, and then reacted at a temperature of 20 to 60 ° C. to silanoyl oxymethyl-methyl. Prepare imidazole derivatives.

Preferably, the compound of formula 2 used as the starting material is t-butylchlorodiphenylsilane, chlorodiphenylsilane, chlorodimethylphenylsilane, chlorotriphenylsilane, chlorodiphenylvinylsilane, chloromethylphenylsilane, chloromethyl It is suitably selected from the group consisting of diphenylsilane and chlorodimethyltoylsilane.

The silanoyl oxymethyl-methyl imidazole derivative represented by Chemical Formula 1 is excellent in inhibiting melanin production and applied to the human body as a composition for inhibiting melanin production and a cosmetic composition for skin whitening, thereby providing excellent melanin production inhibitory effect and skin whitening effect. You can get it.

According to a preferred experimental example of the present invention, when treated with silanoyl oxymethyl-methyl imidazole derivatives of the formula (1) to rat melanoma cells (B-16 melanoma cells), it was found that exhibits a very strong melanin production inhibitory effect . This result means that the silanoyl oxymethyl-methyl imidazole derivative is applied to the skin of humans to exhibit skin whitening effect. Furthermore, it is known from the various known documents that silanoyl oxymethyl-methyl imidazole derivatives are known to be safe for humans, and thus they are preferably applicable as melanogenesis inhibitors and skin lightening agents.

The silanoyl oxymethyl-methyl imidazole derivative according to the present invention is a cosmetic composition for inhibiting melanin production and skin whitening, and is appropriately selected according to the absorption, inactivation rate, excretion rate, age, sex and condition of the active ingredient in the skin. Can be selected, preferably 0.000001 of the total weight. To 10.0% by weight, more preferably 0.0001 to 10% by weight, and more preferably 0.01 to 10% by weight. If the content of the silanoyl oxymethyl-methyl imidazole derivative is 0.0001 If it is less than the weight%, no obvious effect can be expected, and if it exceeds 10% by weight, the effect is not increased compared to the increase in the amount of inclusion.

The composition for inhibiting melanin production and the cosmetic composition for skin whitening according to the present invention include an external ointment, a cream, a foam, a lotion, a pack, a soft water, an emulsion, a foundation, a makeup base, an essence, a soap, a liquid detergent, a bath, a sunscreen cream, Or it may be prepared in a formulation such as sun oil.

In addition, the composition for inhibiting melanin production of the present invention and the cosmetic composition for skin whitening are common ingredients, for example, oil, water, surfactant, moisturizer, lower alcohol, thickener, chelating agent, coloring agent, preservative, A fragrance etc. can be mix | blended suitably.

Hereinafter, preferred examples are provided to help understanding of the present invention, but the following examples are merely to illustrate the present invention, and the scope of the present invention is not limited to the following examples.

Preparation Example 1: Preparation of tert-butyldiphenylsilanyloxymethyl-5-methyl-1-imidazole (4- (t-butyldiphenylsilanyloxymethyl) -5-methyl-1H-imidazole)

Tertiarybutyldiphenylsilaneyloxymethyl-5-methyl-1-imidazole was prepared according to Scheme 2 below.

First, 1.5 g of oxymethyl-5-methyl imidazole was dissolved in 150 ml of tetrahydrofuran, 2.9 ml of triethylamine was added dropwise, and stirred for 5 minutes. Then, 2.84 ml of t-butylchlorodiphenylsilane (tert-butyl-chloro-diphenylsilane) was added and stirred at room temperature. Subsequently, when the starting material disappeared completely, 150 ml of ethylacetate was added, washed 2-3 times with 100 ml of water, and water was removed with anhydrous magnesium sulfate (Anhydrous Magnesium Sulfate).

Subsequently, the organic solvent was distilled under reduced pressure, and then tube chromatography (silica gel: 230-400 mesh) was used to obtain 2.8 g (yield 77%) of the reaction product by nuclear magnetic resonance analysis ( ¹ H-NMR) and mass spectrometry. Confirmed.

¹ H NMR (CDCl ₃ , 300 MHz) δ 7.65 (m, 4H), 7.55 (s, 1H), 7.42 (m, 7H), 4.68 (s, 2H), 2.04 (s, 3H), 1.07 (s, 9H)

MS = 351 (M + H ⁺ )

Preparation Example 2 Preparation of 4-Diphenylsilanyloxymethyl-5-methyl-1H-imidazole

As shown in Scheme 3 below, using the same method as in Example 1 except for using chlorodiphenylsilane instead of t-butylchlorodiphenylsilane (tert-butyl-chloro-diphenylsilane) 2.9 g, yield 76%) was obtained by nuclear magnetic resonance analysis ( ¹ H-NMR) and mass spectrometry.

¹ H NMR (CDCl ₃ , 300 MHz) δ 7.54-7.36 (m, 9H), 7.18 (m, 1H), 4.79 (s, 2H), 2.359 s, 3H).

MS = 295 (M + H ⁺ )

Preparation Example 3: Preparation of dimethylphenylsilanyl oxymethyl-5-methyl-1-imidazole (4-dimethylphenylsilanyloxymethyl-5-methyl-1H-imidazole)

As shown in Reaction Scheme 4, the target product was used in the same manner as in Example 1 except for using chlorodimethylphenylsilane instead of tert-butyl-chloro-diphenylsilane. 2.8 g, yield 66%) was obtained by nuclear magnetic resonance analysis ( ¹ H-NMR) and mass spectrometry.

¹ H NMR (CDCl ₃ , 300 MHz) δ 7.30 (m, 5H), 7.18 (m, 1H), 5.05 (s, 2H), 2.35 (s, 3H).

MS = 360 (M + H ⁺ )

Preparation Example 4 Methyltriphenylsilanyloxymethyl-5-methyl-1-imidazole (5-Methyl-4-triphenylsilanyloxymethyl-5-methyl-1 H -imidazole)

As shown in Scheme 5 below, the target product was prepared in the same manner as in Example 1 except for using chlorotriphenylsilane instead of tert-butyl-chloro-diphenylsilane. 2.7 g, yield 76%) was obtained by nuclear magnetic resonance analysis ( ¹ H-NMR) and mass spectrometry.

¹ H NMR (CDCl ₃ , 300 MHz) δ 7.54-7.36 (m, 15H), 7.18 (m, 1H), 5.05 (s, 2H), 2.35 (s, 3H).

MS = 233 (M + H ⁺ )

Preparation Example 5 Diphenylvinyl silanyloxymethyl-5-methyl-1-imidazole (4- (Diphenylvinylsilanyloxymethyl) -5-methyl-1 H -imidazole)

As shown in Scheme 6 below, the target product was used in the same manner as in Example 1 except for using chlorodiphenylvinylsilane instead of tert-butyl-chloro-diphenylsilane. (3.1, yield 83%) was obtained and confirmed by nuclear magnetic resonance analysis ( ¹ H-NMR) and mass spectrometry.

¹ H NMR (CDCl ₃ , 300 MHz) δ 7.54-7.36 (m, 11H), 7.18 (m, 1H), 5.20 (m, 1H), 5.05 (s, 2H), 2.35 (s, 3H).

MS = 309 (M + H ⁺ )

Preparation Example 6 5-methyl (4-methylphenylsilanyloxymethyl-5-methyl-1-imidazole) (5-Methyl-4- (methylpheylsilanyloxymethyl) -5-methyl-1 H -imidazole)

As shown in Scheme 7 below, the target product (3.3) was used in the same manner as in Example 1 except for using chloromethylphenylsilane instead of tert-butyl-chloro-diphenylsilane. g, yield 78%) was obtained by nuclear magnetic resonance analysis ( ¹ H-NMR) and mass spectrometry.

¹ H NMR (CDCl ₃ , 300 MHz) δ 7.30 (m, 5H), 7.18 (m, 1H), 4.80 (s, 2H), 2.35 (s, 3H), 0.66 (s, 3H).

MS = 233 (M + H ⁺ )

Preparation Example 7 5- (4-Methyl-methyldiphenylsilanyloxymethyl-5-methyl-1-imidazole) (5-Methyl-4- (methyldiphenylsilanyloxymethyl) -5-methyl-1 H -imidazole)

As shown in Scheme 8 below, the same method as in Example 1 was used except that chloromethyldiphenylsilane was used instead of tert-butyl-chloro-diphenylsilane. The target product (2.5 g, yield 66%) was obtained and confirmed by nuclear magnetic resonance analysis ( ¹ H-NMR) and mass spectrometry.

¹ H NMR (CDCl ₃ , 300 MHz) δ 7.54-7.36 (m, 10H), 7.18 (m, 1H), 5.05 (s, 2H), 2.35 (s, 3H), 0.66 (s, 3H).

MS = 360 (M + H ⁺ )

Preparation Example 8: Dimethyl paratoyl silanyl oxymethyl-5-methyl-1-imidazole (4- (Dimethyl-p-tolylsilanyloxymethyl) -5-methyl-1 H -imidazole)

As shown in Scheme 9 below, using the same method as in Example 1 except for using chlorodimethyltoylsilane instead of tert-butyl-chloro-diphenylsilane 2.8 g, yield 70%) was obtained by nuclear magnetic resonance analysis ( ¹ H-NMR) and mass spectrometry.

¹ H NMR (CDCl ₃ , 300 MHz) δ 7.30 (m, 5H), 7.18 (m, 1H), 5.05 (s, 2H), 2.35 (s, 3H), 0.66 (s, 6H).

MS = 247 (M + H ⁺ )

Experimental Example 1 melanin production inhibitory effect

    The silanoyl oxymethyl-methyl imidazole derivatives obtained in Preparation Examples 1 to 9 were added to the culture medium of B-16 mouse melanoma cells to test the whitening effect at the cellular level. (Lotan R. , Lotan D. Cancer Res. 40: 3345-3350, 1980).

At this time, the silanoyl oxymethyl-methyl imidazole derivative was added to a culture medium of B-16 melanoma cells with a hydroquinone solution, respectively, in a final concentration of 2 mg / ml, and then cultured for 3 days, followed by trypsin treatment. After removing from the culture vessel by centrifugation, melanin was extracted. Add 1 ml of sodium hydroxide solution (1N concentration), boil for 10 minutes to dissolve melanin, and measure the absorbance at 400 nanometer (nm) using a spectrophotometer to determine the amount of melanin produced per unit cell count (10 ⁶ cells). It was carried out by the method represented by the absorbance, the relative melanin production relative to the control was calculated as the inhibition rate (%) and the results are shown in Table 2 below.

Inhibitory effect of melanin production at the cellular level sample Melanin production % Inhibition Control group (no addition) 0.04 ± 0.004 - Preparation Example 1 0.016 ± 0.002 66% Preparation Example 2 0.015 ± 0.002 68% Preparation Example 3 0.017 ± 0.001 64% Preparation Example 4 0.020 ± 0.002 57% Preparation Example 5 0.018 ± 0.002 62% Preparation Example 6 0.018 ± 0.002 62% Preparation Example 7 0.021 ± 0.001 55% Preparation Example 8 0.020 ± 0.002 57% Hydroquinone (1ug / ml) 0.025 ± 0.002 47%

* Number of iterations = 3

 According to Table 2, the silanoyl oxymethyl-methyl imidazole derivatives presented in the present invention have comparable melanin production inhibitory ability against cultured mouse melanoma cells when compared with hydroquinone, a known whitening substance. Can be.

Hereinafter, the formulation example of the cosmetic containing silanoyl oxymethyl-methyl imidazole which concerns on this invention is shown by the following formulation example.

Formulation Examples 1 to 8 and Comparative Example 1: External Ointment for Skin Whitening

 ingredient Production example (% by weight) Comparative example One 2 3 4 5 6 7 8 One Stearic acid 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 Cetanol 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 Potassium hydroxide 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0 glycerin 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 Propylene glycol 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 antiseptic Quantity Quantity Quantity Quantity Quantity Quantity Quantity Quantity Quantity incense Quantity Quantity Quantity Quantity Quantity Quantity Quantity Quantity Quantity Purified water to 100 to 100 to 100 to 100 to 100 to 100 to 100 to 100 to100 Preparation Example 1 0.3 - - - - - - - - Preparation Example 2 - 0.3 - - - - - - - Preparation Example 3 - - 0.3 - - - - - - Preparation Example 4 - - - 0.3 - - - - - Preparation Example 5 - - - - 0.3 - - - - Preparation Example 6 - - - - - 0.3 - - - Preparation Example 7 - - - - - - 0.3 - - Preparation Example 8 - - - - - - - 0.3 -

Experimental Example 2: Pigmentation Measurement

To determine the degree of pigmentation of the cream prepared in the formulation was carried out as follows.

20 healthy males and females were placed in the lower hips of each arm with 6 holes of 7 mm diameter in two rows of aluminum foil, and 60mJ / cm ² light was irradiated using ORIEL solar simulator 1000W at a distance of 10cm from the arm. .

The irradiated site was well washed with 70% aqueous ethanol solution before irradiation, and twice a day from 3 days before irradiation to 3 weeks after irradiation, and a pair of bases prepared according to Preparation Examples 1 to 8 and Comparative Example 1 were applied to the same row in pairs. Was

In each case, the degree of pigmentation of the preparation example and the comparative example was visually determined, and the degree of suppression of the pigmentation of the preparation example compared to the comparative example was evaluated in two stages of 'effective' and 'no effect'. It is shown in Table 4 below.

 Pigmentation Inhibitory Effects of Creams Containing Silanoyl Oxymethyl-Methyl Imidazole Derivatives Experimental substance Effective (persons) No difference (persons) Formulation Example 1 11 9 Formulation Example 2 10 10 Formulation Example 3 10 10 Formulation Example 4 11 9 Formulation Example 5 10 10 Formulation Example 6 12 8 Formulation Example 7 10 10 Formulation Example 8 12 8

As shown in Table 4, the cream containing silanoyl oxymethyl-methyl imidazole derivatives prepared according to Preparation Examples 1 to 8 according to the present invention exhibits a whitening effect on at least 10 or more of 20 subjects. And no adverse effect was observed in the skin. These results show that the silanoyl oxymethyl-methyl imidazole derivatives presented in the present invention are safe and highly effective blemishes or freckles improving or skin whitening agents.

The composition for inhibiting melanin production and the cosmetic composition for skin whitening of the present invention include silanoyl oxymethyl-methyl imidazole derivatives as an active ingredient, thereby inhibiting melanin production of the skin, and improving blemishes and freckles, and skin whitening effects are very excellent. It is preferably used as a melanogenesis inhibitor and skin lightening agent.

Claims (10)

Melanin production inhibiting composition comprising a silanoyl oxymethyl-methyl imidazole derivative represented by the following formula (1) as an active ingredient: [Formula 1]

Wherein R _1, R ₂ and R ₃ are each the same or different to a hydrogen atom, C ₃ to C ₇ of the straight or branched chain alkyl group, C ₂ to C ₇ straight or branched chain type alkenyl groups and C ₅ to C ₇ of the Is selected from the group consisting of cycloalkenyl groups, n is an integer of 0 or 1. The method according to claim 1, wherein R ₁ , R ₂ and R ₃ is selected from the group consisting of a hydrogen atom, an alkyl group of C ₁ to C ₄ , an alkenyl group of C ₂ to C ₅ , and a phenyl group, n is a composition for inhibiting melanin production, characterized in that an integer of 0 or 1. The method of claim 1, wherein the silanoyl oxymethyl-methyl imidazole derivative, 1) tertiarybutyldiphenylsilaneyloxymethyl-5-methyl-1-imidazole; 2) diphenylsilaneyl oxymethyl-5-methyl-1-imidazole; 3) dimethylphenylsilaneyl oxymethyl-5-methyl-1-imidazole; 4) methyltriphenylsilaneyloxymethyl- 5-methyl-1-imidazole; 5) diphenylvinylsilanyloxymethyl- 5-methyl-1-imidazole; 6) methyl-methylphenylsilanyloxymethyl- 5-methyl-1-imidazole; 7) methyl-methyldiphenylsilaneyloxymethyl- 5-methyl-1-imidazole; And 8) Dimethyl paratoyl silanyl oxymethyl- 5-methyl-1-imidazol composition for inhibiting melanin production, characterized in that selected from the group consisting of. The composition for inhibiting melanin production according to claim 1, wherein the composition for inhibiting melanin production comprises 0.000001 to 10% by weight of silanoyl oxymethyl-methyl imidazole derivative based on the total weight of the composition. The composition of claim 1, wherein the composition for inhibiting melanin production is an external ointment, cream, foam, lotion, pack, soft water, latex, foundation, makeup base, essence, soap, liquid cleanser, bath agent, sunscreen cream, and sun oil. Melanin inhibiting composition having a formulation selected from the group consisting of. Cosmetic composition for skin whitening comprising silanoyl oxymethyl-methyl imidazole derivative represented by the following formula (1) as an active ingredient: [Formula 1]

Wherein R _1, R ₂ and R ₃ are each the same or different to a hydrogen atom, C ₃ to C ₇ of the straight or branched chain alkyl group, C ₂ to C ₇ straight or branched chain type alkenyl groups and C ₅ to C ₇ of the Is selected from the group consisting of cycloalkenyl groups, n is an integer of 0 or 1. The method according to claim 6, wherein R ₁ , R ₂ and R ₃ is selected from the group consisting of a hydrogen atom, an alkyl group of C ₁ to C ₄ , an alkenyl group of C ₂ to C ₅ and a phenyl group, n is an integer of 0 or 1, the cosmetic composition for skin whitening. The method of claim 6, wherein the silanoyl oxymethyl-methyl imidazole derivative, 1) tertiarybutyldiphenylsilaneyloxymethyl-5-methyl-1-imidazole; 2) diphenylsilaneyl oxymethyl-5-methyl-1-imidazole; 3) dimethylphenylsilaneyl oxymethyl-5-methyl-1-imidazole; 4) methyltriphenylsilaneyloxymethyl- 5-methyl-1-imidazole; 5) diphenylvinylsilanyloxymethyl- 5-methyl-1-imidazole; 6) methyl-methylphenylsilanyloxymethyl- 5-methyl-1-imidazole; 7) methyl-methyldiphenylsilaneyloxymethyl- 5-methyl-1-imidazole; And 8) Dimethyl paratoyl silanyl oxymethyl- 5-methyl-1-imidazol Cosmetic composition for skin whitening, characterized in that selected from the group consisting of. The cosmetic composition for skin whitening according to claim 6, wherein the cosmetic composition for skin whitening comprises silanoyl oxymethyl-methyl imidazole derivatives in an amount of 0.000001 to 10% by weight based on the total weight of the composition. The cosmetic composition for skin whitening according to claim 6, wherein the cosmetic composition for skin whitening is an external ointment, cream, foam, lotion, pack, soft water, latex, foundation, makeup base, essence, soap, liquid cleanser, bath agent, sunscreen cream, and sun oil Cosmetic composition for skin whitening having a formulation selected from the group consisting of.